Category: Redefining Every Stage Investments (RESI)

The Redefining Every Stage Investments (RESI) Conference is an ongoing conference series that provides an international venue for life science companies across Biotech, Medtech, Diagnostics and Healthcare IT and to source investors from around the globe, create relationships, and eventually, secure funding.

Boost Your Exposure at Healthtech Partnering Week – Apply for the Innovator’s Pitch Challenge (IPC)

~ Next Phase Admin ~ Leave a comment

By Claire Jeong, Vice President of Investor Research, Asia BD, LSN

claireWe are now accepting applications for the Innovator’s Pitch Challenge at Healthtech Partnering Week, taking place January 11-15, 2021.

The Innovator’s Pitch Challenge (IPC) is an opportunity for start-ups to boost their exposure and showcase their technology to conference attendees, particularly investors. Each company will be provided with a dedicated landing page on our virtual agenda, which will include their pitch video, slide deck, executive summary, and any other materials companies wish to feature on their page. In addition, the companies pitch to a panel of judges featuring active investors and prominent industry experts, and participate in a live Q&A. These sessions will provide valuable insights and feedback, as well as build connections between fundraising founders and potential strategic partners.

If you are a fundraising CEO, you do not want to miss out on this opportunity.

Example of a Company’s Landing Page

Meet the Innovator’s Pitch Challenge Finalists

~ Next Phase Admin ~ Leave a comment

By Karen Deyo, Senior Investor Research Analyst, LSN

The Innovator’s Pitch Challenge is a popular feature at the Redefining Early Stage Investments (RESI) conference taking place November 17-19, 2020. Selected companies pitch directly to a panel of investors working within their sector. Company information, including a pre-recorded pitch, executive summary, pitch deck, and additional supporting materials are hosted on a dedicated webpage accessible through the event live agenda. Throughout the conference, these companies participate in a live Q&A with relevant investors. Registered attendees can mark their calendars directly through the partnering platform and attend the Q&A to learn more about the up-and-coming technology in their field.

We are happy to announce that the following companies are participating in the Innovator’s Pitch Challenge at Digital RESI November next week. Make sure to check out their dedicated pages and block off your schedule to attend the live Q&A sessions! If you haven’t yet signed up, but would like to join, there is still time to register. We hope you’ll join us!

Therapeutics

Medical Device

Diagnostics, Digital Health & R&D Services

Who’s Taking the Stage at Digital RESI November?

~ Next Phase Admin ~ Leave a comment

By Claire Jeong, Vice President of Investor Research, Asia BD, LSN

claireNext week’s digital partnering event, Redefining Early Stage Investments (RESI), taking place November 17-19, is fast-approaching! RESI conferences provide early-stage players powerful partnering opportunities, but go beyond traditional pitching and partnering by offering insightful expert investor panels. These panels pull back the curtain to what investors look for when sourcing assets and developing partnerships. RESI’s panels highlight key perspectives relevant to the early-stage life science and healthcare ecosystem.

Panel themes range from Corporate Venture Capital to Early Stage Therapeutics Investments and will provide deep insights on investor perspectives, how investors and strategic partners view the current landscape, and how fundraising entrepreneurs can effectively approach the right investors, among other topics.

Registered attendees can block off their calendars directly in the partnering platform to make sure they don’t miss a panel that fits their interest. If you haven’t yet registered and are interested in hearing from key industry players, it is still not too late to register! Sign up to start partnering and learning from these key players. We hope you’ll join us!

EARLY STAGE THERAPEUTICS INVESTORS

  • Sascha Berger, Partner, TVM Capital Life Science
  • Z Haroon, Chairman and General Partner, Julz Co LLC
  • Sunil Shah, CEO, O2h Ventures
  • Yaniv Sneor, Founding Member, Mid Atlantic Bio Angels
  • Travis Whitfill, Partner, Bios Partners

DIAGNOSTICS INVESTORS

  • Martin Pfister, Senior Investment Manager: Life Sciences, High-Tech Gründerfonds
  • Diana Saraceni, Founder, Managing Director, Panakes Partners
  • Noel Jee, Principal, Illumina Ventures
  • Jorge Aquino, Director, Ventures, Johns Hopkins Technology Ventures
  • Jorge Ramirez, Principal, H.I.G. BioHealth Partners

MEDICAL DEVICE INVESTORS

  • Flora Yao, Founding Partner, Ivy Elite Capital
  • George Li, Managing Partner, Proxima Ventures
  • Gary Gershony, Medical Device Committee, Life Science Angels
  • Rachel Rea, Director, Strategy & Portfolio Management, Surgical Innovations, Medtronic
  • Mishael Zohar, Associate, OrbiMed Advisors LLC

DIGITAL HEALTH

  • Ute Mercker, Investment Director, IBB Ventures
  • Terri Mead, Founder, Class Bravo Ventures
  • Sven Dethlefs, EVP Global Marketing & Portfolio, Teva Pharmaceuticals Industries
  • Sean Cheng, Senior Investment Manager, Philips Health Technology Ventures
  • Richard Proscia, Senior Associate, Providence Ventures

BIG PHARMA

  • Ravi Ramadas, Director, Immunology External Innovation, Global BD&L, Sanofi
  • Lisa Mendoza, Director, External Research & Alliances, Open Innovation – Digital Technologies, Bayer
  • Ronald Dorenbos, Founder and Managing Director, BioFrontline Ltd.
  • Tim Luker, Senior Director, Emerging Technology & Innovation, Corporate Business Development, Eli Lilly & Co

CORPORATE VENTURE CAPITAL

  • Andy Merken, Partner, Corporate and Securities Co-Chair, Life Sciences, Burns & Levinson
  • David Hwang, Managing Director, Early Stage Partnerships, Agilent Technologies
  • Carrie Hurwitz Williams, Partner, McKesson Ventures
  • Victor Stone, Partner, Takeda Ventures
  • Hakan Goker, Vice President, Healthcare Team, M Ventures

New Sponsoring Opportunities at LSN’s Quarterly Healthtech Partnering Week

~ Next Phase Admin ~ Leave a comment

By Dennis Ford, Founder and CEO, Life Science Nation (LSN); Creator, Redefining Early Stage Investment (RESI) Conference Series, 4D Meets AI Conference, and Longevity, Health & Innovation Conference; Architect, Focus on Cures Accelerator; Owner, Boston Innovation Capital (BIC); Member, SPIC/FINRA Advisory Firm

New Sponsorship Program

Life Science Nation (LSN) has built a sourcing and funding global superstructure featuring elite global technology assets and the investors, Pharma and channel partners who seek them. The international infrastructure consists of early-stage life science buyers and sellers, each with updated curated data profiles that are matched up at LSN’s dedicated partnering events. In 2021, these partnering events will join forces to become a global quarterly Healthtech Partnering Week, featuring RESI, 4D Meets AI, as well as Longevity, Health & Innovation partnering conferences. These events will take place in conjunction with global life science hubs, enabling fundraising CEOs to leverage the partnering system as part of a global capital raising campaign. Sponsorship at these events help companies gain unprecedented visibility into the early-stage life science community, and also leverage LSN’s close-knit network of key decision-makers to make promising connections with future clients and strategic partners. The sponsorship program is designed to help organizations increase global exposure through high visibility branding and messaging, target and source assets and strategic partnerships, advertise products and services through programming and direct contact with industry leaders. To learn more about sponsorship opportunities, download our sponsorship brochure.

The Digital Experience: 2020-2021

The Covid-19 pandemic has challenged the global economy and business climate, but LSN has not slowed down. On the contrary, LSN has accelerated since March 2020 through its focus on deal-making. LSN partnering conferences are experiential, interactive, and focus on building relationships and successful transactions. LSN stands out among other educational life science networks for this mission. LSN’s continued mission has been to connect buyers and sellers to move the needle in the early-stage life science partnering arena. Partnering is neither a trend nor conference sideshow, rather an essential matching exercise that needs curated profiles of both the buyer and the seller, and an integrated search feature that can match companies based on mutual fit.

Matching Buyers and Sellers Together

LSN matches buyers and sellers based on stage of development and product fit through curating detailed up-to-date profiles of every constituent of the two groups. This method enables efficient partnering at LSN events and avoids empty tables and ill-fitting meetings. Matching requires profile curation and detailed database management, therefore, a large volume of LSN resources go towards maintaining and constantly improving this imperative feature. In addition to efficient matching, LSN offers educational resources available to fundraising executives including LSN CEO, Dennis Ford’s book, The Life Science Executive Fundraising Manifesto which guides scientist-entrepreneurs through the concepts of building branding and messaging. Additional resources include free tutorials and webinars aimed at preparing CEOs to book meetings with investors effectively, which includes adroit messaging and a 4-step follow-up process, which has been proven to advance the needle from 4-6 meetings to 12-20 meetings. Fundraising is a numbers game and understanding how to get the most of out of these global partnering events is the key to a successful capital raise.

Partnering is an Ongoing Experiential Activity

The LSN partnering theme is that it is a crucial, ongoing, and experiential activity. LSN believes that partnering cannot be done once or twice a year, as business deals do not work that way. In the life science arena, it can take 9-18 months to put a deal together. This means that all buyers and sellers need a simple, low-cost, straight-forward vehicle to meet and engage monthly in order to find new opportunities for their respective pipelines, advance a conversation, continue to vet and develop a relationship, or close deals. LSN’s recent entrée of digital events has proved and invigorated this concept. Life science is a virtual third-party service domain, making a new, hybrid, global ecosystem timely and compelling. We look forward to advancing life-saving deals through our Healthtech Partnering Weeks, and hope you’ll consider partnering with us. To learn more about sponsorship opportunities, download our sponsorship brochure.

Want to learn more? The business development team at Life Science Nation is available to answer questions and share additional details to help you meet your partnership goals!

International
Greg Mannix
Chief Conference Officer, Vice President International BD
g.mannix@lifesciencenation.com

West Coast (USA)
Candice He
Global Investment Strategist
c.he@lifesciencenation.com
​
East Coast (USA)
Ashley Zborowski
Director of Business Development
a.zborowski@lifesciencenation.com

The Innovator’s Pitch Challenge at Digital RESI November and Healthtech Partnering Week

~ Next Phase Admin ~ Leave a comment

By Karen Deyo, Senior Investor Research Analyst, LSN

The Innovator’s Pitch Challenge (IPC) applications are now open for 4D Meets AI and Longevity, Health & Innovation at Healthtech Partnering Week. Through the IPC, start-ups can pitch directly to a panel of investors during a live Q&A session. Each company receives a dedicated page on the event live agenda, featuring a 4-minute pre-recorded pitch hosted as well as supplemental materials, for easy access and optimal exposure. Early-stage companies are encouraged to apply, along with a pitch deck and an executive summary. Once selected to pitch, companies pay a $500 pitching fee and submit their video and supplemental materials for investors to review prior to the live session.
The IPC is coming up fast at Digital RESI November. In two weeks, RESI will feature  live pitch sessions with investor Q&A. Check out a partial list of pitching companies.

See What Investors Are Saying about The Innovator’s Pitch Challenge

“It was a very economical use of time; the investors got to ask their important questions and the Innovators got a good idea of the most pressing questions from the investors point of view.”
William Kuziel, MedPro Investors
“The Pitch Sessions are a great opportunity to connect with startup CEOs and learn more about their work…It really has been an effective and efficient way to make connections, create deal flow and help startups raise money for their upcoming raises.”
Mayank Taneja, OSF Healthcare
“I look forward to LSN’s events because they provide an opportunity for our venture capital firm to find promising companies with exceptional technologies. The organization and technology platform make it very easy to hear numerous pitches from founders.”
Nat Brinn, VC23
“The Pitch Sessions were a great opportunity to engage with the CEO/Founders of very innovative Life Science startups. Despite the COVID-related transition from in-person to virtual meetings, the RESI team did an outstanding job organizing these sessions, ensuring that the live Q&A was very productive, and facilitating follow-up with these exciting companies.”
Gary Gershony, Life Science Angels / BayMed Venture Partners

Partnering with IGIA Pharmaceuticals

~ Next Phase Admin ~ Leave a comment

By Rory McCann, Marketing Manager & Conference Producer, LSN

In this interview, I sit down to chat with Dr. Jeff Livingstone on his recent move to CEO of Igia Pharmaceuticals, and how partnering events continue to serve his companies, even as an industry veteran. Jeff shares insight into the early days of Igia, and how he uses partnering to expand their goals and reach children and families affected by rare and orphan diseases, specifically Noonan Syndrome.
Listen to the conversation and learn more about RESI November and Healthtech Partnering Week.

Digital RESI November Panel Spotlight on Early-Stage Therapeutics

~ Next Phase Admin ~ Leave a comment

By Joey Wong, Investor Research Analyst, LSN

The Digital RESI November Conference is less than 2 weeks away! Digital RESI is the premier partnering conference experience for the early-stage entrepreneur and their strategic partners, featuring a match-based partnering platform in addition to educational and insightful content, such as workshops, pitch sessions, and live investor panels spanning the sectors of drugs, devices, diagnostics, and digital health.

The Early Stage Therapeutics Investors panel will feature five investors with extensive experience in early-stage therapeutics to discuss their investment mandates and how their own investment process works.

Fundraising executives developing therapeutic assets will get an insightful look at the strategies used by early-stage therapeutic investors to assess companies at the earliest, riskiest stage of development. They can learn to position their companies as an attractive investment opportunity under the current investment landscape. The live session will feature:

Yaniv Sneor, Founding Member, Mid Atlantic Bio Angels (Moderator)

Yaniv Sneor is a (reformed) physicist, who made the transition into the business world after being bitten by the entrepreneurial bug. Yaniv has been involved in founding, growing, managing and re-engineering companies for the past 25+ years, in multiple industries. He ran companies of different sizes and at different life-stages, led re-structuring activities, purchased and sold multiple companies, and negotiated and integrated joint ventures and strategic relationships.Yaniv is one of the founders of MABA – Mid Atlantic Bio Angels (bioangels.net) a life science angel investor group. He is president of Blue Cactus Consulting (bluecactusconsulting.com), and CEO of Native State Therapeutics, a recently-formed biotechnology company, in the neurodegenerative space.

Sascha Berger, Partner, TVM Capital Life Science

Sascha Berger, PhD, joined the TVM Capital Life Science team in Munich in 2016. He is active in deal flow generation, investment due diligence, deal and exit transactions, investor communication as well as corporate finance aspects of the fund. Sascha has a strong financial background with almost ten years of professional transaction and strategy experience. He has a track-record of concluding 20 M&A transactions, five of those he led as responsible project manager in his previous role as Senior M&A Manager in a PE backed global corporation. He was a core team member in a successful EUR 2.5bn revenue cross-border merger and successfully coordinated global merger clearance procedures (USA, China, EU, Korea). During his studies he already supported TVM Capital Life Science part-time; he supported the IPO of a German technology company at Deutsche Bank and advised Private Equity funds at Deloitte in summer internships. He lived in Singapore and New York, co-founded a student initiative on Entrepreneurship in Munich and in his spare time enjoys triathlon and world travelling.

Sunil Shah, CEO, O2h Ventures

Sunil has been active in the early stage biotech community in the UK since the mid 1990’s, his respective thesis at Cambridge addressed issues in virtualised networks in science. In 2003, following a brief period at PA Consulting Group Oxygen Healthcare was formed providing discovery services to biotech and pharma. The company grew into a team of 350 employees and was acquired by Piramal Enterprises (NSE:PEL) in 2011-2013. o2h Ventures was co-founded by Sunil in 2013. In the last 4 years, it has co-founded four companies with UK based academics and entrepreneurs, provided consultancy services to five companies, held Chairman or Director level positions in nine companies, built up a portfolio of twenty early stage investments, and executed early stage drug discovery research projects for fifteen different companies.

Travis Whitfill, Partner, Bios Partners

Travis Whitfill is a Partner at Bios Partners. His background began in molecular biology and biochemistry at the MD Anderson Cancer Center and Duke University. He is the co-founder of several startup companies. He is on the board of several companies, including Incysus Therapeutics. He brings a strong background in entrepreneurship and business and was acknowledged as Forbes’ 30 Under 30 in 2018. He’s also the Senior Analyst at Bios Research. He also is an Associate Research Scientist in the Departments of Pediatrics and Emergency Medicine at Yale. Mr. Whitfill has led numerous grant-funded projects, holds nearly a dozen patents, and has co-authored over 40 publications. Mr. Whitfill received degrees from Yale University (MPH) and Dallas Baptist University (BS) and is working on a PhD from University College London.

Z Haroon, Chairman and General Partner, Julz Co LLC

Julz Co is an investment management company focused on investing in early-stage healthcare companies in the area of therapeutics, medical devices, services and digital healthcare. The company has offices in Chapel Hill, North Carolina, USA and Suzhou, China. Julz invests globally in companies that have novel and proprietary technology addressing a vital market need and are driven by experienced management teams.

Partnering at RESI is open! But there is still time to register to participate and join these investors at the next Digital RESI, November 17 -19. Don’t miss out on the many elements that make Digital RESI the leader in the early-stage deal-making ecosystem.